The heart failure drugs market, valued at USD 7.84 billion in 2025, is projected to reach USD 9.19 billion in 2026 and USD 12.31 billion by 2035. Heart failure is a chronic condition in which the heart is unable to pump sufficient blood into different organs. Further, in order to mitigate the growing incidence, pharmaceutical companies have developed heart failure drugs that can target wide range of conditions, such as managing fluid build-up, improving cardiac contractility, controlling blood p...

The GLP-1 receptor agonist market size, valued at USD 78 billion in 2025, is projected to reach USD 101.4 billion in 2026 and USD 180 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035. In recent years, there has been a notable shift in consumer lifestyles driven by the growing influence of social media, celebrity endorsements and direct-to-consumer advertising. This has led to a surge in the demand for weight loss and type 2 diabetes treatment solutions, which...

The global anti-obesity drugs market, valued at USD 28.2 billion in 2025, is projected to reach USD 45.1 billion in 2026 and USD 106.5 billion by 2035, representing a CAGR of 10.0% during the forecast period 2026 to 2035. In terms of route of administration, parenteral route captures the highest share of the current market.Based on the distribution channel, retail and online pharmacies are likely to capture the highest share of the current market. In terms of key geographical regions, North Amer...

The global non-small cell lung cancer market size is estimated to grow from USD 23.8 billion in 2025 to USD 26.4 billion in 2026 and USD 56.0 billion by 2035, representing a CAGR of 8.7% during the forecast period. It is worth highlighting that among all the forms of non-small cell lung cancer, squamous cell carcinoma is one of the most common types and it may develop due to prolonged use of tobacco. In fact, the World Health Organization report shows that smoking is the main cause of lung cance...

The global biopharmaceutical excipients manufacturing market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 6.3 billion by 2035, representing a CAGR of 6.4% during the forecast period 2026 to 2035. Emerging innovations, particularly in lipid-based excipients for mRNA vaccines and therapeutics, are further expanding the excipient landscape. Coupled with the rising trend in outsourcing and growing regulatory support for novel excipients, the use of biopha...

The global atrial fibrillation market, valued at USD 20.9 billion in 2025, is projected to reach USD 21.4 billion in 2026 and USD 38.7 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. The market includes both treatment drugs and devices for atrial fibrillation (AFib). In 2024, the CDC identified AFib as the most common heart arrhythmia treated in the US. The number of Americans affected is projected to reach 12.1 million by 2030, with AFib contributing to rou...

The global microbial fermentation CMO market, valued at USD 3.8 billion in 2025, is projected to reach USD 4.3 billion in 2026 and USD 9.6 billion by 2035, with a CAGR of 9.4% during the forecast period 2026 to 2035. Presently, there are a number of traditional and innovative microbial expression systems / platforms, based on bacteria, fungi and yeast, which are used for manufacturing a variety of conventional and complex biologics. Contract manufacturers engaged in this domain have forged sever...

The global cancer metabolism based therapeutics market, valued at USD 2.7 billion in 2025, is projected to reach USD 3.7 billion in 2026 and USD 26.3 billion by 2035, with a CAGR of 24.3% during the forecast period 2026 to 2035. With respect to route of administration, oral route (close to 85%) dominates the current market. Based on target disease indication, in 2026, breast cancer captures the largest cancer metabolism based therapeutics market value (over 45%). In terms of geographical regions...

The global systemic lupus erythematosus market size, valued at USD 2,669 million in 2025, is projected to reach USD 2,471 million in 2026 and USD 6,547 million by 2035, representing a CAGR of 11.4% during the forecast period 2026 to 2035. Based on the route of administration, intravenous route captures the largest share (close to 70%) of the current market; this trend is unlikely to change in the future. Amongst the types of therapy, combination therapies capture the most (nearly 95%) of the cur...

The global next generation immune checkpoint inhibitors market, valued at USD 15.4 billion in 2025, is projected to reach USD 17.5 billion in 2026 and USD 20.9 billion by 2035. Based on type of molecule, biologics are likely to hold the highest market share (close to 97%), in the current year. Based on geographical regions, North America is projected to capture the majority share of the market, in 2035. In terms of sales forecast for therapies, Darzalex will hold the highest market share by secu...

The global biopharmaceutical contract manufacturing market, valued at USD 28.0 billion in 2025, is projected to reach USD 31.0 billion in 2026 and USD 63.9 billion by 2035, with a CAGR of 8.3% during the forecast period 2026 to 2035. In terms of type of expression system used, mammalian expression systems currently hold around 80% of the market share, due to their superior ability to produce complex proteins by mimicking human biology. In terms of scale of operation, commercial scale segment cap...

The global rapid microbiology testing solutions market, valued at USD 560 million in 2025, is projected to reach USD 603 million in 2026 and USD 1,463 million by 2035, representing a 10.3% CAGR during the forecast period 2026 to 2035. In 2035, North America is likely to have high rapid microbiology testing solutions market size, capturing around 40% of the overall market share. This dominance is attributed to the presence of a well-established pharmaceutical manufacturing base, early adoption of...

The global anti-aging drugs market, valued at USD 79 million in 2025, is projected to reach USD 150 million in 2026 and USD 2,807 million by 2040, with a 23.3% CAGR during the forecast period 2026 to 2040. The National Institute of Health around 7.2 million American citizens aged above 65 and above live with diseases, such as Alzheimer. In January 2025, the Dog Aging Project secured a USD 7 million grant to expand its clinical trial of an anti-aging drug. It is worth highlighting that the mar...

The continuous manufacturing market valued at USD 2,599 million in 2025, is project to reach USD 2,847 million in 2026 and USD 4,193 million by 2035, representing a CAGR of 4.4% during the forecast period 2026 to 2035. This continuous process minimizes downtime and maximizes equipment utilization, leading to higher efficiency and productivity, reduced unit costs (around 40-50%), and expediated drug commercialization. Amongst the publicly revealed partnerships and collaborations in the continuous...

The global nasal drug delivery market, valued at USD 6.1 billion in 2025, is projected to reach USD 8.1 billion in 2026 and USD 26.8 billion by 2035, with a 14.2% CAGR during the forecast period 2026 to 2035. The global market highlights the market segmentation of nasal drug delivery, based upon their target indication into acute repetitive clusters, anaphylaxis, COVID-19, dry eye disease, hypoglycemia, influenza, major depressive disorder, migraine, nasal polyps, and prader-willi syndrome.

Researchers are currently focusing on the development of advanced stem cells, platelet-rich plasma (PRP), monoclonal antibodies (mAb), nutritional supplements, and pain management medication to improve motor function and comfort. In July 2025, Gallant (US) announced USD 18 million funding support to bring the first USFDA approved ready-to-use stem cell therapy to veterinary medicine to improve mobility in pets.

The global NAMPT inhibitor market size is estimated to be worth USD 0.2 billion in 2027 and is anticipated to reach USD 1.3 billion by 2040 at a CAGR of 15% during the forecast period. According to the American Cancer Society, in 2022, 9.7 million people died from the cancer disease globally, and 35 million new cases of cancer are predicted to be diagnosed by 2050. This mounting number of cancer cases and growing demand for effective treatment are the key drivers for market growth over this pro...

The global blood brain barrier market, valued at USD 38 million in 2025, is projected to reach USD 252 million in 2026 and USD 2,904 million by 2035, with a 31.2% CAGR during the forecast period 2026 to 2035. Neurological disorders are the second highest cause of death and the leading cause of disability, worldwide. In 2021, it was reported that nearly 3.4 billion global population suffer from some form of disorder that affects the functioning of the CNS. More than 6 million people are reported...

The single use bioreactors market, valued at USD 4.32 billion in 2025, is projected to reach USD 4.81 billion in 2026 and USD 10.48 billion by 2035, with a CAGR of 9.03% during the forecast period, 2026 to 2035. The ongoing technological advancements focused on the development of improved versions of biosensors and single use bioreactor bags are likely to encourage the biopharmaceutical companies to adopt disposable bioreactors for continuous bioprocessing, representing a lucrative opportunity f...

The cell culture media market, valued at USD 9.0 billion in 2025, is projected to reach USD 9.7 billion in 2026 and USD 17.5 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. In July 2024, Merck KGaA invested EUR 6.6 million at Jiangsu, China site to expand the cell culture media manufacturing and production capabilities. In October 2024, Evonik established a global competence network for cell culture solutions in order to increase its offering of system solut...